Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical Responses to Prostate-specific Membrane Antigen Radioguided Salvage Lymphadenectomy for Prostate Cancer Recurrence: Results from a Prospective Exploratory Trial.
Weiner AB, Ells Z, Meyer C, Dahlbom M, Sennung D, Varughese D, Ludwig VB, Carlucci G, Grant R, Czernin J, Calais J, Reiter RE. Weiner AB, et al. Among authors: dahlbom m. Eur Urol Open Sci. 2024 Oct 15;70:36-42. doi: 10.1016/j.euros.2024.09.004. eCollection 2024 Dec. Eur Urol Open Sci. 2024. PMID: 39483519 Free PMC article.
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.
Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J. Calais J, et al. Among authors: dahlbom m. Lancet Oncol. 2019 Sep;20(9):1286-1294. doi: 10.1016/S1470-2045(19)30415-2. Epub 2019 Jul 30. Lancet Oncol. 2019. PMID: 31375469 Free PMC article. Clinical Trial.
Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer.
Stuparu AD, Capri JR, Meyer CAL, Le TM, Evans-Axelsson SL, Current K, Lennox M, Mona CE, Fendler WP, Calais J, Eiber M, Dahlbom M, Czernin J, Radu CG, Lückerath K, Slavik R. Stuparu AD, et al. Among authors: dahlbom m. J Nucl Med. 2021 Jul 1;62(7):989-995. doi: 10.2967/jnumed.120.256263. Epub 2020 Dec 4. J Nucl Med. 2021. PMID: 33277393 Free PMC article.
Radiation Dosimetry of 99mTc-PSMA I&S: A Single-Center Prospective Study.
Urbán S, Meyer C, Dahlbom M, Farkas I, Sipka G, Besenyi Z, Czernin J, Calais J, Pávics L. Urbán S, et al. Among authors: dahlbom m. J Nucl Med. 2021 Aug 1;62(8):1075-1081. doi: 10.2967/jnumed.120.253476. Epub 2020 Dec 4. J Nucl Med. 2021. PMID: 33277398 Free article.
The Impact of Monosodium Glutamate on 68Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging Study.
Armstrong WR, Gafita A, Zhu S, Thin P, Nguyen K, Alano R, Lira S, Booker K, Gardner L, Grogan T, Elashoff D, Allen-Auerbach M, Dahlbom M, Czernin J, Calais J. Armstrong WR, et al. Among authors: dahlbom m. J Nucl Med. 2021 Sep 1;62(9):1244-1251. doi: 10.2967/jnumed.120.257931. Epub 2021 Jan 28. J Nucl Med. 2021. PMID: 33509974 Free PMC article. Clinical Trial.
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort.
Calais J, Gafita A, Eiber M, Armstrong WR, Gartmann J, Thin P, Nguyen K, Lok V, Gosa L, Grogan T, Esfandiari R, Allen-Auerbach M, Quon A, Bahri S, Gupta P, Gardner L, Ranganathan D, Slavik R, Dahlbom M, Herrmann K, Delpassand E, Fendler WP, Czernin J. Calais J, et al. Among authors: dahlbom m. J Nucl Med. 2021 Oct;62(10):1440-1446. doi: 10.2967/jnumed.121.261982. Epub 2021 May 20. J Nucl Med. 2021. PMID: 34016732 Free PMC article. Clinical Trial.
136 results